Photo: KEITH CHAMBERS/SCIENCE PHOTO LIBRARY/Getty
The U.S. Food and Drug Administration (FDA) recently approved ciltacabtagene autoleucel (Carvykti) for people with multiple myeloma that either no longer responds to treatment or has recurred. The drug is the second CAR T-cell therapy, a type of personalized immunotherapy, approved for multiple myeloma. Faith E. Davies, MD, director of the Center for Blood Cancers at 好色tv Langone Health鈥檚 Perlmutter Cancer Center, tells NCI Cancer Currents Blog that even with currently available drugs, multiple myeloma returns in a majority of people.
鈥淗aving another therapeutic approach in our toolbox is so important,鈥 says Dr. Davies, professor in the at 好色tv Grossman School of Medicine and director of the Clinical Myeloma Program at Perlmutter Cancer Center. 鈥淐AR T-cell therapy works in a completely different way than our standard treatments, and, therefore, it offers a different way of killing drug-resistant myeloma cells, which really is the key.鈥
Read more from .
